Premium
P4‐302: RVT‐101, a 5‐ht6 receptor antagonist, as adjunctive therapy with donepezil in adults with mild‐to‐moderate Alzheimer's disease: Responder analysis
Author(s) -
Lombardo Ilise,
Ramaswamy Geetha,
Piscitelli Stephen C.,
Friedhoff Lawrence
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.08.132
Subject(s) - tolerability , donepezil , placebo , medicine , adverse effect , antagonist , clinical endpoint , pharmacology , clinical trial , dementia , disease , receptor , pathology , alternative medicine
(p1⁄40.002) relative to placebo. The effect size was large; Cohen’s d was 0.67 at Week 6 and 0.92 at Week 12. To further quantify the clinical significance of MMFS-01, results on TMT-B test were compared to normative data from age-matched cognitivelynormal controls. MMFS-01 treatment restored impaired executive function of the subjects nearly back to that of age-matched cognitively-normal controls, suggesting MMFS-01 is clinically significant. Conclusions:The current study demonstrates the potential of MMFS-01 for treating cognitive impairment in elderly.